标题: |
神经内分泌肿瘤生长抑素受体显像及核素治疗临床指南(2022版) |
title: |
Clinical Guidelines for Somatostatin Receptor Imaging and Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumor (2022) |
版本: |
原创版 |
version: |
Original |
分类: |
标准指南 |
classification: |
Standard guideline |
领域: |
诊疗 |
field: |
Diagnosis and Treatment |
国家和地区: |
中国 |
Country and
region:
|
China |
指南使用者: |
|
Guide users:
|
|
证据分级方法: |
本指南主要纳入两类证据:
(1)高水平循证医学证据(1类),专家组一致同意,强力推荐(A);
(2)证据水平较低(2类),但专家组基本同意,中等推荐(B)。
其他等级的证据暂不纳入本指南。 |
Evidence grading
method:
|
This consensus mainly includes two types of evidence:
First, high-level evidence-based medical evidence (Category 1), which is unanimously agreed by the expert group and strongly recommended (A);
Second, the level of evidence is slightly lower (Category 2), but the expert group basically agrees, and it is moderately recommended (B).
Other levels of evidence will not be currently included. |
制定单位: |
中华医学会核医学分会,中国医促会神经内分泌肿瘤分会 |
Formulating unit: |
Chinese Society of Nuclear Medicine, Chinese Neuroendocrine Tumor Society |
注册时间: |
2022-04-15 |
Registration time: |
注册编号: |
IPGRP-2022CN229 |
Registration number: |
指南制订的目的: |
|
Purpose of the guideline:
|
|